PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma
AbstractBackground:Targeted therapies with BRAF plus MEK inhibitors (BRAFi; MEKi)represent the major treatment strategy for patients with BRAF-mutated metastatic melanoma(MM). Previous analyses suggested a correlation between programmed death-ligand 1 (PD-L1)expression in tumour tissues and the outc...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
European journal of cancer
Year: 2017, Jahrgang: 88, Pages: 67-76 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.10.026 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2017.10.026
|
| Verfasserangaben: | Katrin Schaper-Gerhardt, Steven Okoyea, Rudolf Herbst, Jens Ulrich, Patrick Terheyen, Claudia Pfö̈hler, Jochen S. Utikal, Alexander Kreuter, Peter Mohr, Edgar Dippel, Imke Satzger, Antje Sucker, Dirk Schadendorf, Selma Ugurel, Ralf Gutzmera |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666439800 | ||
| 003 | DE-627 | ||
| 005 | 20220816162622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190528r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.10.026 |2 doi | |
| 035 | |a (DE-627)1666439800 | ||
| 035 | |a (DE-599)KXP1666439800 | ||
| 035 | |a (OCoLC)1341225572 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schaper-Gerhardt, Katrin |e VerfasserIn |0 (DE-588)1024063569 |0 (DE-627)71908976X |0 (DE-576)367881438 |4 aut | |
| 245 | 1 | 0 | |a PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma |c Katrin Schaper-Gerhardt, Steven Okoyea, Rudolf Herbst, Jens Ulrich, Patrick Terheyen, Claudia Pfö̈hler, Jochen S. Utikal, Alexander Kreuter, Peter Mohr, Edgar Dippel, Imke Satzger, Antje Sucker, Dirk Schadendorf, Selma Ugurel, Ralf Gutzmera |
| 264 | 1 | |c 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.05.2019 | ||
| 500 | |a Available online 28 November 2017 | ||
| 520 | |a AbstractBackground:Targeted therapies with BRAF plus MEK inhibitors (BRAFi; MEKi)represent the major treatment strategy for patients with BRAF-mutated metastatic melanoma(MM). Previous analyses suggested a correlation between programmed death-ligand 1 (PD-L1)expression in tumour tissues and the outcome of targeted therapies. This study investigatedPD-L1 as a potential predictive biomarker of BRAFi-based targeted therapies in MM patients | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 88(2018), Seite 67-76 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma |
| 773 | 1 | 8 | |g volume:88 |g year:2018 |g pages:67-76 |g extent:11 |a PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2017.10.026 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190528 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 7 | ||
| 999 | |a KXP-PPN1666439800 |e 3480032214 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Schaper-Gerhardt, Katrin","role":"aut","given":"Katrin","roleDisplay":"VerfasserIn","family":"Schaper-Gerhardt"},{"display":"Utikal, Jochen","role":"aut","given":"Jochen","roleDisplay":"VerfasserIn","family":"Utikal"}],"physDesc":[{"extent":"11 S."}],"name":{"displayForm":["Katrin Schaper-Gerhardt, Steven Okoyea, Rudolf Herbst, Jens Ulrich, Patrick Terheyen, Claudia Pfö̈hler, Jochen S. Utikal, Alexander Kreuter, Peter Mohr, Edgar Dippel, Imke Satzger, Antje Sucker, Dirk Schadendorf, Selma Ugurel, Ralf Gutzmera"]},"relHost":[{"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"id":{"issn":["1879-0852"],"eki":["266883400"],"zdb":["1468190-0"]},"disp":"PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanomaEuropean journal of cancer","note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","publisher":"Elsevier ; Pergamon Press"}],"part":{"volume":"88","text":"88(2018), Seite 67-76","pages":"67-76","year":"2018","extent":"11"},"recId":"266883400","titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb","roleDisplay":"Herausgebendes Organ"},{"roleDisplay":"Herausgebendes Organ","display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology","roleDisplay":"Herausgebendes Organ"}]}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"language":["eng"],"recId":"1666439800","id":{"doi":["10.1016/j.ejca.2017.10.026"],"eki":["1666439800"]},"title":[{"title":"PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma","title_sort":"PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma"}],"note":["Gesehen am 28.05.2019","Available online 28 November 2017"]} | ||
| SRT | |a SCHAPERGERPDL1STATUS2018 | ||